Pearle Vision in Las Veegas, NV - Optometrist

Pearle Vision is a Optometrist based in Las Veegas, Nevada. Pearle Vision is licensed to practice in Nevada (license number ) and their current practice location is 7090 S Rainbow Blvd, Ste 100, Las Veegas, Nevada. It can be reached at their office (for appointments etc.) via phone at (702) 452-2020.

NPI number for Pearle Vision is 1184173015 and their current mailing address is 2021 N Rainbow Blvd, Ste 100, Las Vegas, Nevada. Pearle Vision does not participate in medicare program and thus does not accept medicare assignments. The facility's NPI Number is 1184173015.

Contact Information

	Pearle Vision
	7090 S Rainbow Blvd, Ste 100, Las Veegas, NV 89118
	(702) 452-2020
	Not Available

Healthcare Provider's Profile

Full Name	Pearle Vision
Type	Facility
Speciality	Optometrist
Location	7090 S Rainbow Blvd, Las Veegas, Nevada
Accepts Medicare Assignments	Does not participate in Medicare Program. The facility may not accept medicare assignment.

NPI Data:

NPI Number: 1184173015
Provider Enumeration Date: 10/04/2016
Last Update Date: 10/04/2016

Medical Identifiers

Medical identifiers for Pearle Vision such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1184173015	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	(Nevada)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Pearle Vision is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Pearle Vision 2021 N Rainbow Blvd, Ste 100, Las Vegas, NV 89108 Ph: (702) 733-6764	Pearle Vision 7090 S Rainbow Blvd, Ste 100, Las Veegas, NV 89118 Ph: (702) 452-2020

News Archive

Prior treatment may impact efficacy of ACT-TIL in patients with metastatic melanoma

Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) as patients naïve to these treatments.

Net income of Biomet increased 33.8% to $80.8M in first quarter of 2014

Biomet, Inc. announced today financial results for its first quarter ended August 31, 2013.

New way to protect neurons that express mutant huntingtin proteins

By using a model, researchers at the University of Montreal have identified and "switched off" a chemical chain that causes neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis and dementia. The findings could one day be of particular therapeutic benefit to Huntington's disease patients. "We've identified a new way to protect neurons that express mutant huntingtin proteins," explained Dr. Alex Parker of the University of Montreal's Department of Pathology and Cell Biology and its affiliated CRCHUM Research Centre.

Defense Secretary Gates announces creation of independent panel to study military health care conditions

Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).

Pearle Vision - Optometrist in Las Veegas, NV